Healx is a rare disease biotechnology company that uses generative AI for drug discovery. Healx utilizes advanced artificial intelligence (AI) and machine learning technologies to identify potential drug candidates and repurpose existing drugs for new therapeutic applications. By focusing on drug repurposing, Healx aims to find new uses for existing medications, leveraging their known safety profiles and reducing the risk and cost associated with developing new drugs from scratch.
Total raised
$115M
Last stage
Series C
Investors
Andreas Bender
Lecturer in Molecular Informatics at the Centre for Molecular Sciences Informatics at Cambridge University.
Tim Guilliams
Tech entrepreneur from the Cambridge Cluster, passionate about using AI to accelerate treatments for rare diseases. Holds a PhD in Biophysical Neuroscience from the University of Cambridge. Also Co-Founder of the Cambridge Rare Disease Network (CRDN).
LinkedInDavid Brown
Co-inventor of Viagra and former Global Head of Drug Discovery at Roche. Has founded and led multiple life sciences ventures.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.
